# XtalPi

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xtalpi

- Industry: Pharmaceuticals
- Headquarters: Shenzhen, China
- Website: www.xtalpi.com
- Total disclosed funding: $831M
- Latest round: Series D (Aug 12, 2021)
- Investors on record: 31

## About

Established in 2015 and based in Shenzhen, China, XtalPi Inc. operates as an AI pharmaceutical intended to integrate quantum physics and artificial intelligence to accelerate the development of new pharmaceutical drugs. It has sub-branch offices in Shanghai, Beijing, and Boston. The co-founder and chairman of the company, Shuhao Wen graduated from the Massachusetts Institute of Technology. The company has obtained more than 160 patents. It cooperates with Qilu Pharmaceuical, Huadong Medicine, and other pharmaceutical companies. In June 2024, the company raised HKD 337.7 million in Pre-IPO and listed on the Hong Kong Exchange and Clearing Ltd. 

The company mainly uses quantum chemistry, artificial intelligence, big data, and cloud computing technology for artificial intelligence drug research and development. It provides drug discovery services, chemistry services, and laboratory automation solutions. The drug discovery services include small molecule drug discovery and macromolecule drug discovery. The chemistry services include chemical synthesis services and drug solid form research and development. The R&D technologies, services and products can be used in biomedicine, chemical industry, new material, and other fields.

The company generates revenue by providing drug research and development services, drug discovery services, chemistry services, and laboratory automation solutions.

The company will expand intelligent automation solutions and global business and will use the funds raised from the IPO to enhance the company's R&D capabilities and commercialization capabilities.

## Funding rounds

- Series D, Aug 12, 2021, $400M — OrbiMed Advisors, Hong Shan, 5Y Capital, Sino Biopharmaceutical Limited, RRJ Capital, Artisan Partners, Tencent Holdings Limited, Neumann Capital Management, CMH Healthcare Investment, IMO Ventures, Hermitage Capital Group
- Series C, Sep 28, 2020, $319M — Hong Shan, CITIC Capital Holdings, 5Y Capital, Parkway Capital Investors, SIG Asia Investment, China International Capital Corporation, Tencent Investment, CITIC Securities, PICC Capital Equity Investment, Shunwei Capital, CMB International Asset Management, Mirae Asset Venture Investment, SB Investment Advisers, China Life Capital, Oceanpine Capital, IMO Ventures, Fangyuan Financial Group
- Series B, Oct 25, 2018, $46M — SIG Asia Investment, China Life Capital
- Series B, Oct 24, 2018, $46M — Shanghai International Group, China Life Capital, Yael Capital
- Series B, Jan 24, 2018, $15M — Hong Shan, Google Inc., Tencent Investment
- Series A, Jan 6, 2016, $1.2M — ZhenFund, Frees Fund
- Series A, Dec 15, 2015, $3.7M — Tencent Investment
- Angel, Dec 1, 2010 — Fortune Capital

## Investors

- Fortune Capital — Angel
- Tencent Investment — Series A, Series B, Series C
- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Series A
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Series A
- Hong Shan — Series B, Series C, Series D
- Google Inc. — Series B
- Shanghai International Group — Series B
- China Life Capital — Series B, Series C
- Yael Capital (https://capitalatlas.ai/funds/yael-capital) — Series B
- SIG Asia Investment (https://capitalatlas.ai/funds/sig-asia-investment) — Series B, Series C
- CITIC Capital Holdings (https://capitalatlas.ai/funds/citic-capital-holdings) — Series C
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C, Series D
- Parkway Capital Investors (https://capitalatlas.ai/funds/parkway-capital-investors) — Series C
- China International Capital Corporation (https://capitalatlas.ai/funds/china-international-capital-corporation) — Series C
- CITIC Securities — Series C
- PICC Capital Equity Investment (https://capitalatlas.ai/funds/picc-capital-equity-investment) — Series C
- Shunwei Capital (https://capitalatlas.ai/funds/shunwei-capital) — Series C
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series C
- Mirae Asset Venture Investment (https://capitalatlas.ai/funds/mirae-asset-venture-investment) — Series C
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series C
- Oceanpine Capital (https://capitalatlas.ai/funds/oceanpine-capital) — Series C
- IMO Ventures (https://capitalatlas.ai/funds/imo-ventures) — Series C, Series D
- Fangyuan Financial Group — Series C
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series D
- Sino Biopharmaceutical Limited — Series D
- RRJ Capital (https://capitalatlas.ai/funds/rrj-capital) — Series D
- Artisan Partners — Series D
- Tencent Holdings Limited — Series D
- Neumann Capital Management — Series D
- CMH Healthcare Investment (https://capitalatlas.ai/funds/cmh-healthcare-investment) — Series D
- Hermitage Capital Group (https://capitalatlas.ai/funds/hermitage-capital-group) — Series D